The study, performed by Yelena Budovskaya, PhD, co-founder of TruMe Labs, showed that Ponce de Leon Health's Rejuvant LifeTabs reduced the biological age of users by an average of 8.5 years. Biological age is assessed via a DNA biomarker test that measures DNA methylation, according to the firm. LifeTabs contain a proprietary active ingredient, LifeAKG, which has been shown in preclinical animal studies to increase the lifespan and healthspan (length of healthy life) in mammalian models.

Ponce de Leon is currently enrolling participants in a randomized, double-blind, placebo-controlled clinical trial that will be conducted at Indiana University Medical Center later this year.

Ponce de Leon distributes TruMe's TruAge Index, a home-use epigenetic age test, it said. Ponce de Leon has eight patents pending for TruAge-related inventions.

From DNA to precision medicine, researchers discuss breakthroughs in cancer research
From the use of novel technologies such as machine learning and CRISPR, to gaining a deeper understanding of the genetic and molecular drivers of cancer,...